TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Likert score for ASL signal detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ret‐He reference intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in Ret‐He among iron-deficient infants at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in Ret‐He among iron-deficient infants at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative cooperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: propofol requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: analgesia efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived extreme postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of other pain complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma interleukin‐6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma interleukin‐10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Need for transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Inadequate analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Central nervous system side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: reduction in alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic prescribing rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Referral for chest X-ray
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recovery rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 4-month implant success rate
Endpoint domain: Mortality/survival
Primary endpoint: tissue thickness gain (keratinized tissue)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV₁ improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Carotid intima-media thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevention of acute vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete control of postoperative nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to PMCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Being intoxicated during the last 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary coagulation as determined by thrombin-antithrombin complexes, factor VIIa, and soluble tissue factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pulmonary fibrinolysis as reflected by plasminogen activator activity and plasminogen activator inhibitor type 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Suppression of the anticoagulant protein C pathway indicated by soluble thrombomodulin, protein C, and activated protein C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: histologic scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for additional clinic support resources
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 9.3-km run time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of fexofenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of genetic services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Knowledge of breast cancer risk factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: family-QODD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in natural killer T-cell (NKT) numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sustained decrease in hepatitis B virus (HBV) DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: irradiated small bowel volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composite of all-cause death and new Q-wave myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in alcohol craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Sensitivity Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiometabolic Syndrome Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median change in the Incremental Shuttle Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breathlessness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COR AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ACTH AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: UFC values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: depression status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean values of tumor necrosis‐α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean values of interleukin‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean values of adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: treatment modality outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertigo control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children with bactericidal titers >= 1:4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative (13)C recovery in breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximal (13)C enrichment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Action plan creation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Openness to using e-cigarettes in the future
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Implicit attitudes towards e-cigarettes as a safer alternative
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive spontaneous affective reactions to e-cigarette stimuli
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric mean ratio (GMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of opioid-positive urine test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients remaining in treatment at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported opioid use during weeks 1 through 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eyes gaining ≥15 ETDRS letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMT reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in spoken vocabulary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAL gains (>3 mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of response to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response time to simple brief tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with detrusor overactivity (DO) on urodynamic evaluation (UDE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leakage with detrusor overactivity (DO) on UDE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximum detrusor pressure during involuntary contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Digestive comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: lower encephalopathy grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: absence of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: higher Apgar score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bruxist time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Times of bruxism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse reaction of respiratory tract
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyrotropin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: complete stone removal rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Development of CIN grade 3 or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of HPV testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value for CIN3 or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations of neurohormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urine magnesium excretion (UME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cell magnesium content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hernia recurrence
Endpoint domain: Mortality/survival
Primary endpoint: buccopalatal bone width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of maternal acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: drop in venous pH below 7.32
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cobb angle improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to reach an absolute neutrophil count (ANC) of 0.5 x 10(9)/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median duration of neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ocular Surface Disease Index (OSDI) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expressible meibomian glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: In-stent restenosis (ISR) frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean deltaFFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ED severity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of erection score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum protein S100B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Return to give blood
Endpoint domain: Mortality/survival
Primary endpoint: ovulation induction outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Development of atopic dermatitis (AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: beta-cell function (insulin secretory rate in relation to glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: glucagon levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: sprint performance (10 m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change-of-direction performance (T-half)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: jumping performance (squat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased mindfulness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decreases in depression, anxiety, and stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of Re‐Engage uptake
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients receiving appropriate diagnostic work-ups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acceleration of gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diet performance
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Rate of weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IOP reduction without medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure freedom at 18 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood lead level greater than 0.48 mumol/L (10 micrograms/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HAM-A score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analog Scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry Disability Index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection rates of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to reach the cecum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dilatation ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-experienced discomfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Demand for narcotic analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cord blood pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum disulfide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentration of TNF‐α, IL‐6 and IL‐8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: levels of CD(3)(+), CD(4)(+), CD(4)(+)/CD(8)(+) ratio and NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Activation reduction in response to painful pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical effectiveness of SSE for idiopathic scoliosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of SSE for idiopathic scoliosis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Seven-day point prevalence of smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cLDL reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: subjective smoking satisfaction and enjoyment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Annual increase of outpatient days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Annual decrease in inpatient days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Annual net cost savings per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total length of hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of modified oral brush biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial blood pressure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: self-reported injuries
Endpoint domain: Adverse events/effects
Primary endpoint: out‐of‐lane driving events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: John's Drowsiness Score (JDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reperfusion of M1 occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coma recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Low-density lipoproteins (LDL) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High-density lipoproteins (HDL) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of analgesic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of hepatitis B e antigen (HBeAg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete anti‐viral response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence at 2-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence at 6-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean DASH score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in PRWE score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean residual volar angulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiation dose of ULD-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiological outcomes
Primary endpoint: Image quality of ULD-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of non-calcified pulmonary nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of miR-126
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of rTMS vs ECT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cessation of analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Development of drug-induced AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biomarker levels before AKI onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AUROC for AKI prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hazard ratio for exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating levels of soluble tumor necrosis factor receptor‐75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: No/slow reflow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Function of the RITA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of anginal attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved physical quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dose reductions in anti-ischemic medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: saturated fatty acid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL oxidation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes